Arterial Disease Across Vascular Beds․ Lipoprotein(a) as a Causal Risk Factor
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared on X:
”Lipoprotein(a) [Lp(a)] is not just about coronary disease.
Robust genetic and population data confirm Lp(a) as a causal risk factor across multiple vascular beds.
- Peripheral Arterial Disease (PAD): Rising Lp(a) levels show a clear, stepwise association with PAD risk—up to ~3-fold higher risk at extreme concentrations.
- Major Adverse Limb Events (MALE): In patients with PAD, high Lp(a) markedly increases the risk of amputations and repeat revascularizations.
- Abdominal Aortic Aneurysm (AAA): Elevated Lp(a) is consistently associated with higher AAA risk, supported by Mendelian randomization.
- Inflammation matters—but doesn’t negate Lp(a) risk: Lp(a)-associated cardiovascular risk persists independently of hsCRP levels, in both primary and secondary prevention.
Clinical takeaway: Lp(a) identifies residual vascular risk beyond LDL-C and traditional factors—supporting routine measurement and future targeted therapy.
Phase 3 Lp(a)-lowering outcome trials may redefine prevention across coronary and non-coronary vascular disease.
Open Access here.
Article:Lipoprotein(a) in cardiovascular disease with focus on peripheral arterial disease, major adverse limb events, abdominal aortic aneurysms and interaction with low-grade inflammation
Authors: Peter E. Thomas, Signe Vedel-Krogh, Pia R. Kamstrup, Børge G. Nordestgaard
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 16, 2026, 06:05Wolfgang Miesbach on Jacob Lund’s Study: How to Define FVIII Bioequivalence
-
Jan 16, 2026, 05:52Piotr Czempik Shares His Latest Contribution to Acta Haematologica Polonic
-
Jan 16, 2026, 05:44Florian Piekarski on Perioperative Blood Management When Allogeneic Transfusion is Not Aaccepted
-
Jan 16, 2026, 05:00Plaque Rupture and Thrombosis
-
Jan 16, 2026, 04:51Higher-Dose Clotting Factor Prophylaxis Does Not Reduce Postpartum Hemorrhage in Women with von Willebrand Disease
-
Jan 16, 2026, 04:48Reza Shojaei on Plasma Donation as Life-Changing Medicine in Motion
-
Jan 16, 2026, 04:11Open-Label Extension Study of Marstacimab: Pfizer Has Reported a Fatal Event
-
Jan 16, 2026, 04:11Why is DVT More Common In the Left Leg? Dr Raheel Moazzam’s New Study Gives Answers!
-
Jan 15, 2026, 22:00Maira Dastgir N on Microvascular Dysfunction in Geriatrics